Future treatment aspects in the protection from diabetes-induced sperm failure Limitations and strengths Conclusions BACKGROUND: Hyperglycemia can result from a loss of pancreatic beta-cells or a decline in their function leading to decreased insulin secretion or may arise from insulin resistance and variable degrees of inadequate insulin secretion resulting in diabetes and related comorbidities. To date several reviews have addressed the issue of diabetes-related male infertility but most have focused on how metabolic syndrome causes the decline in male fertility. However, a comprehensive overview as to how diabetes-induced hyperglycemia impairs
Introduction
In 2010, an estimated 48.5 million couples worldwide were infertile with male factor infertility contributing to~40-50% of these cases, and with as many as 2% of all men exhibiting suboptimal sperm parameters (Mascarenhas et al., 2012; Kumar and Singh, 2015) . Hyperglycemia is characterized by blood glucose levels exceeding normal levels and is diagnosed either by impaired fasting blood glucose levels (IFG) or by impaired glucose tolerance (IGT): IFG is a state with blood glucose levels repeatedly exceeding normal blood glucose concentrations above 7 mmol/l, while IGT is a state with blood glucose levels greater than 11 mmol/l 2 h after a 75 g oral glucose load. IGF and IGT are independent parameters for the diagnosis of diabetes mellitus (DM) and have been used as a diagnostic criterion in recent studies of diabetes as a cause of male factor infertility (World Health Organisation, 2006; Alves et al., 2013a Alves et al., , 2013b . These studies suggested a negative impact of DM on erectile and ejaculation function, as well as a reduction in semen volume, sperm counts, sperm motility and abnormal sperm morphology (Alves et al., 2013b) . Given that the global burden of diabetes is constantly increasing with an estimated prevalence of 422 million people in the year 2014, there will be an increasing number of men of reproductive age, as there is a rise in the number of childhood and adolescent males with DM (Silink, 2002; Wild et al., 2004; Agbaje et al., 2007; Guariguata et al., 2014; World Health Organization, 2016) . Furthermore, male infertility is now recognized as a sign of male health impairment (Eisenberg et al., 2015; Ventimiglia et al., 2015) , particularly when sexual dysfunction is present (Lotti et al., 2016) .
Glucose metabolism in health and disease
Under physiological conditions, carbohydrates, mainly consisting of starch or disaccharides such as sucrose and lactose, account for the main source of energy income in the body (Lunt and Vander Heiden, 2011) . Through intestinal digestion these carbohydrates are reduced to monosaccharides, such as glucose, as well as low amounts of fructose and lactose, and are resorbed in enterocytes and hepatocytes, where they are metabolized further via various pathways, including glycolysis, the pentose-phosphate-pathway, hexosamine pathway and glycogenesis ( Fig. 1) (Zierler, 1999; Hay, 2016) . Further pathways for glucose metabolism (Fig. 2) , which have also repeatedly been associated with hyperglycemia-induced damage, include the polyol-pathway and the formation of advanced glycation endproducts (AGEs), as well as the activation of protein kinase C (PKC) (Brownlee, 2001) . Extensive reviews on glucose metabolic pathways can be found in Hay (2016) or Brownlee (2001) .
In order to maintain glucose homeostasis in all cells, glucose uptake is mainly regulated by glucose transporters and glucose regulatory hormones. Glucose transporters comprise sodium-dependent (sodium glucose co-transporter, SGLT) and facilitative glucose transporters Figure 1 Glucose metabolism pathway under physiological conditions. Glucose enters the intracellular space through receptors GLUT 1-4, to enter into the glycolysis pathway. The first metabolite glucose-6-phosphate (G6P) is metabolized further via the glycolysis pathway or via the branching pentose phosphate, hexosamine pathway or gylcolysis. 2PG, 2-phosphoglycerate; 3PG, 3-phosphoglycerate; 6 PG, 6-phosphogluconate; 6PGDH, 6-phosphogluconate dehydrogenase; 6PGL, 6-phosphogluconolactonase; α-KG, α-ketoglutarate; AcCoA, acetyl-CoA; F1,6BP, fructose-1,6-bisphosphate; F2,6BP, fructose-2,6-bisphosphate; F6P, fructose-6-phosphate; G1P, glucose-1-phosphate; G3P, glyceraldehyde-3-phosphate; G6P, glucose-6-phosphate; GlcN-6 P, glucosamine-6-phosphate; GLUT, glucose transporter; NAcGlcN-1 P, N-acetyl d-glucosamine-1-phosphate; NAcGlcN-6 P, N-acetyl d-glucosamine-6-phosphate; OAA, oxaloacetate; PPi, inorganic phosphate; Rib-5 P, ribose-5-phosphate; UDP-Glc, UDP-glucose; UDP-GlcNAc, UDP-N-acetylglucosamine.
(GLUTs), which are sodium-independent (reviewed in (Baud et al., 2016; Mueckler and Thorens, 2013) ).
Besides the glucose transporters, glucose homeostasis is also maintained by the close interaction of glucose-regulatory hormones, which include insulin, glucagon, amylin, glucagone-likepeptide-1 (GLP-1), glucose-dependent insulinotropic peptide, epinephrine, cortisol and growth hormone (GH) (Aronoff et al., 2004) .
Causes of abnormal glucose regulation and associated mechanisms
Glucose dysregulation resulting in hyperglycemia can have several causes, some of which are acquired and others congenital diseases. Acquired disorders of glucose metabolism are hyperglycemia, caused by absolute or relative insulin deficiency; hypoglycemia, due to hyperinsulinism as a consequence of a pancreatic islet cell tumor or the lack of insulin antagonists, such as glucocorticoids, in adrenal insufficiency; carbohydrate malabsorption; and neonatal jaundice caused by a deficiency in glucuronyltransferase activity.
Other than acquired defects in glucose metabolism, congenital glucose disorders mainly affect enzyme functions leading to severe and life-threatening diseases in homozygous carriers. These diseases include galactosemia, fructose intolerance, glycogenosis and inherited hemolytic anemia.
Among these diseases, DM is the disorder that has been studied most extensively in terms of glucose dysregulation thus providing insight into glucose metabolism. Diabetes comprises a group of chronic, metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion and/or insulin action (ADA, 2012) . Left untreated, diabetes leads to chronic hyperglycemia, which is associated with long-term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, nerves, heart and blood vessels (Chavakis et al., 2002; Schmidt et al., 2009; ADA, 2012; Alves et al., 2013a; Hombrebueno et al., 2014; Lo et al., 2015; VenegasPino et al., 2016) . Besides these complications, DM has been Figure 2 Glucose metabolism pathways that are often associated with hyperglycemia-induced damage. Glucose enters the intracellular space through GLUTs or SGLTs into the polyol-pathway, the AGE-formation pathway or into the activation of PKC. AGEs, advanced glycation endproducts; CEL, N(ε)-(carboxyethyl)lysine; CML, N(ε)-(carboxymethyl)lysine; DAG, diacylglycerol; GLUT, glucose transporter; GSH, reduced glutathione; GSSG, glutathione disulfide; NAD, nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine dinucleotide; NADP + , nicotinamide adenine dinucleotide phosphate; NADPH, reduced nicotinamide adenine dinucleotide phosphate; PKC, protein kinase C; SGLT, sodium-glucose linked transporter. discussed in recent years in the context of male reproductive dysfunction since it can lead to erectile and ejaculatory disorders, as well as a reduction in semen volume, sperm counts, sperm motility and abnormal sperm morphology (Alves et al., 2013a) . Being one of the most prominent public health threats in modern societies with a rising prevalence, DM leads to an increase in hyperglycemia-related disorders (Li et al., 2015) .
Several hypotheses about how hyperglycemia causes diabetic complications at a biochemical level have been described, including increased polyol and hexosamine pathway flux, increased AGE formation and activation of PKC isoforms (Brownlee, 2001 ).
Testicular glucose metabolism
The maintenance of spermatogenesis requires the production of lactate from glucose by the Sertoli cell. Therefore, blood-to-germ cell transport of glucose and other metabolic intermediates from the basal into the adluminal compartment is highly controlled, particularly owing to the presence of the blood-testis-barrier (BTB) (Riera et al., 2009) .
To date expression of Glut1, Glut2, Glut3, Glut8 and recently also Glut4 has been demonstrated in the testis (Ulisse et al., 1992; Burant and Davidson, 1994; Kokk et al., 2004; Carosa et al., 2005; Verma and Haldar, 2016) , with Glut1 and Glut3 exhibiting synergistic roles in the maintenance of glucose uptake (Carosa et al., 2005; Galardo et al., 2008) . To the best of our knowledge, the presence of sodium dependent glucose transporters within the testis has not been described. Besides the facilitated glucose transport, it has also been reported that glucose uptake and lactate production by Sertoli cells are regulated by various hormones such as FSH and testosterone (Galardo et al., 2008; Oliveira et al., 2012; Rato et al., 2015b) . Moreover, it was shown that the insulin family of growth factors, comprising insulin, insulin-like growth factors I (IGF1) and II (IGF2) and insulin receptors (INSR) as well as type-I insulin-like growth factor receptor (INS1R), are crucial for the development and function of the testis (Nakayama et al., 1999; Pitetti et al., 2013) . Most interestingly, IGF1 as well as INS1R were shown to be expressed by Sertoli cells, Leydig cells, spermatogonia and spermatocytes. Thus, they are involved in regulation of the energy metabolism of Sertoli cells by regulating the uptake of nucleotides (ATP, GTP, UTP), and the secretion of transferrin, pyruvate, and lactate, suggesting that insulin is actively involved in initiation and maintenance of spermatogenesis (Griswold and Merryweather, 1982; Skinner and Griswold, 1982; Jutte et al., 1983; Borland et al., 1984; MacLean et al., 2013; Griffeth et al., 2014) .
Testicular cells have several metabolic features that tightly control the blood-to-germ cell transport of glucose and other metabolic intermediates. Glucose transport is further regulated via hormonal action of the hypothalamic-pituitary-gonadal (HPG) axis and the presence of the BTB formed by specialized cell junctions between Sertoli cells which have the ability to produce lactate at a very high rate (Alves et al., 2013b) . Since these unique characteristics of glucose metabolism within testicular cells make them prone to changes under diabetic conditions, several clinical and animal studies have focussed on evaluating the molecular mechanisms responsible for the alterations induced in male reproductive potential. While much remains to be determined, it is likely that both the glucose sensing machinery as well as the hormonal control of these cells work in concert to counteract the effects of hyperglycemia and thus play a crucial role in the prevention of subfertility and/or infertility associated with DM (Sjoberg et al., 2013; Alves et al., 2013b; La Vignera et al., 2015) .
Besides the insights into possible mechanisms linking metabolic diseases with male factor subfertility and/or infertility, these data have not distinguished the influence of hyperglycemia itself from other metabolic changes such as obesity or insulin resistance. Hence, the impact of metabolic changes on male reproductive health are often associated with dyslipidemia and subsequent lipid peroxidation, as well as inflammation, conditions that are not necessarily related to hyperglycemia per se (Kasturi et al., 2008) . Moreover, recent studies have uncovered new mechanisms involved in hyperglycemia-induced male subfertility/infertility. Therefore, this systematic review validates studies using T1D as the appropriate disorder to examine the impact of hyperglycemia per se on male reproductive health. The contribution of selected studies to relevant issues of medical practice is examined. Molecular pathways altered by hyperglycemia resulting from the expected increase in glucose transport into testicular cells are discussed. Potentially harmful mechanisms, including enhancement of the activin family of proteins and reduced activity of poly-ADP-ribose polymerase, are discussed. Finally, future directions for the study of molecular mechanisms responsible for these complications as well as options for the treatment of hyperglycemiainduced male infertility are presented.
Methods

Protocol and registration
The protocol of the present study has been registered (PROSPERO ID number: CRD42017070203) in the PROSPERO registry (http://www. crd.york.ac.uk/PROSPERO), an international database for the prospective registration of systematic reviews in health and social care.
defined by hyperglycemia (blood glucose > 11.1 mmol/l) in the absence of obesity. The primary outcomes of these studies were semen quality (volume, motility, morphology, sperm count or concentration, sperm DNA damage or chromatin integrity, sperm aneuploidies and hormonal level) or testicular funtion (morphology or spermatogenesis). We excluded studies on T2D patients or animal models, studies that investigated both T1D and T2D but did not distinguish the outcome clearly, and review articles. Once compliance with all the inclusion/exclusion criteria had been verified, the full text of the selected articles was evaluated for the level of evidence of the results.
Data extraction
We extracted the following information from each study: author/s, year of publication, journal, title of the article, location of the study, age, infertility problem, number of patients or animals (sample size), study design, exposure (intervention), primary outcomes and major findings or principal conclusion. Each report was double-checked by C.C.M. and T.L. in terms of feasibility and fulfillment of inclusion criteria.
Quality assessment in clinical trials
We evaluated and scored the quality of the clinical trials using both customized and published grading criteria (Burns et al., 2011) . The quality scores were assessed in parallel by C.C.M. and T.L., and discrepancies were re-evaluated together. With this system, we assessed the quality of individual studies using the following grading criteria: (A) Trial in full accordance with the aim of the review, T1D characterized by HbA1c or repeated glucose measurements, duration of diabetes and daily insulin dosage; (B) Trial comparing normal with elevated HbA1c or glucose measurements irrespective of diabetes type, incomplete characterization of T1D; (C) Trial comparing diabetics with non-diabetics without giving HbA1c or glucose, or not giving diabetes type in comprehensible way; (D) Trial not related to aim of the review or only abstract available or with incomplete information on diabetic patients or referenced information which is not available in given source. Evidence levels were attributed as follows: (1) RCTs, prospective, homogeneity of results, interventional; (2) Cohort studies with acceptable quality, number of probands and controls adequate to hypothesis, and reasonable homogeneity of results; (3) Case-control or low-quality cohort study; (4) Case report, crosssectional study; (5) Expert opinion. For example, studies with scores C5 and D1 were considered of low quality, while studies with A4 to B1 were considered of acceptable quality. Furthermore, risk of bias was evaluated according to the Cochrane Collaboration (http://www.cochrane.org). Three trials were eligible for complete bias analysis, two of which were classified with low and one with high risk of bias.
Results
Study selection
We identified 808 articles after a primary search of MEDLINEPubmed and 358 from other sources (Cochrane Library and reviews references) (Fig. 3) . By analyzing the titles and abstracts (n = 890), we screened and excluded 598 for reasons of the scope of the study. A total of 292 articles were collected as full texts so that the inclusion/exclusion criteria and quality could be assessed: 81 articles were excluded because they did not meet the inclusion/exclusion criteria, and 14 articles for which no full text was available. After applying all the eligibility parameters, 197 articles were included for qualitative analysis.
Summary of selected studies and design
The articles included 32 clinical and 165 animal studies conducted in 15 and 30 countries, respectively: Argentina, Australia, Brazil, Canada, China, Egypt, Finland, Germany, India, Iran, Israel, Italy, Japan, Cuba, Kuwait, Malaysia, Mexico, The Netherlands, Nigeria, Poland, Portugal, Romania, Russia, Saudi-Arabia, South Africa, South Korea, Spain, Taiwan, Tunisia, Turkey, UK, Ukraine, United Arab Emirates, USA.
General, summarized information on the studies is given in Tables I-III. Clinical studies were conducted on a total of 5598 T1D individuals with a mean age of 33 ± 11 years and a mean diabetes duration of 12 ± 6 years. There was 1 interventional, 3 cohort and 22 case-control as well as four case report/cross-sectional studies.
Animal studies were conducted on a mean number of 38 ± 21.0 animals per study. The mean diabetes duration was 8 ± 9 weeks. There were 56 observational and 109 intervention studies.
Detailed information on the studies is given in Supplementary  Tables 1 and 2 .
Hyperglycemia-related male infertility
The notion that hyperglycemia can compromise male fertility has long been described. Physicians in the 11th century already noticed that men with dysregulated glucose metabolism presented problems related to their sexual functions and difficulties in fathering offspring, describing this condition as a "collapse of the sexual functions" of the male. Accordingly, male infertility is now recognized as a sign of male health impairment (Ventimiglia et al., 2015) , particularly when sexual dysfunction is present (Lotti et al., 2016) .
Clinical studies
Notably, in vivo maintenance of spermatogenesis relies on the uptake and use of glucose (Zysk et al., 1975) , although its concentration in the tubular fluid is very low (Robinson and Fritz, 1981) . For many years, it was suggested that hyperglycemia was a dysfunction associated mostly with ageing, but this concept has changed. It is now assumed that hyperglycemia affects an increasing number of children, adolescents, young adults and men of reproductive age (reviewed in (Alves et al., 2013a (Alves et al., , 2013c ). Of these,~50% of male diabetics presented some degree of subfertility or infertility (La Vignera et al., 2009) . The clinical manifestation of a large spectrum of conditions depended on several factors including age, duration of the disease, the frequency and severity of hyperglycemic/hypoglycemic events, and the degree of glucose control. Unfortunately, this has resulted in heterogeneous patient cohorts that make clinical studies difficult to compare. Here, we have identified 32 clinical studies that focused on the effects of hyperglycemia in resemblant interventional, cohort, case-control or cross-sectional setups. Results from these investigations showed that hyperglycemia was associated with a reduced number of offspring (Holstein et al., 2012; Sjoberg et al., 2013; Wiebe et al., 2014) , going along with multiple alterations in the function of the reproductive tract of male diabetics. These alterations included non-testicular functions, such as retrograde ejaculation (RE) (Kurbatov et al., 2015; Kam et al., 2017) and erectile dysfunction (Schiavi et al., 1985; Wessells et al., 2011) , as well as alterations in sperm parameters and hormone levels.
While health detriments were clearly observed in diabetic men, the effect of hyperglycemia on sperm quality was controversial. Albeit the majority of trials (n = 9) with a total of 132 patients reported a normal sperm count and semen volume (Padron et al., 1984; Murray et al., 1988; Shrivastav et al., 1989; Niven et al., 1995; Agbaje et al., 2008; Mallidis et al., 2009a Mallidis et al., , 2009b Paasch et al., 2011; Roessner et al., 2012) , only two studies including 34 patients found reductions that occurred in the absence of diabetic complications (Garcia-Diez et al., 1991; Agbaje et al., 2007) . Poor glucose control was significantly associated with impairment of sperm motility in 5 studies with 193 patients (Ali et al., 1993a; Niven et al., 1995; Baccetti et al., 2002; Lopez-Alvarenga et al., 2002; La Vignera et al., 2015) . In fact, a more detailed study concerning sperm of T1D men showed that only some parameters associated with sperm motility were altered (i.e. linearity and linear index of straightness of swimming), while others remained unchanged (i.e. track speed, path velocity, progressive velocity, among others) (Niven et al., 1995) . Further, a series of 3 publications with 100 patients indicated that a history of diabetic neuropathy increased the total number of pathologic outcomes in sperm analysis (Ali et al., 1993a (Ali et al., , 1993b (Ali et al., , 1993c .
More recently, a proteome analysis of sperm from T1D men found a distinct profile when compared to that of individuals with normal glycemia (Paasch et al., 2011) . Another sperm analysis from T1D men showed normal standard analysis parameters, such as sperm count, but a higher level of chromatin damage (Agbaje et al., 2007) , which may compromise the fertility potential of those individuals to a larger extent.
The effect of hyperglycemia on hormonal dysregulation was confirmed in some studies (Baccetti et al., 2002; Lopez-Alvarenga et al., 2002; Grossmann et al., 2008; Maric et al., 2010) , but not in others (Cohen et al., 1984; Padron et al., 1984; van Dam et al., 2003; Leal et al., 2012; Rocha et al., 2014) . A single study with individuals exposed to hyperglycemia displayed an abnormal feedback in the HPG-axis linked to a reduced sensitivity in the pituitary to GnRH stimulation, however, it did not become clear to what extent this contributed to a significant impairment of fertility (Baccetti et al., 2002) . Blood levels of testosterone, LH, and FSH were rarely changed in the absence of concomitant diseases. By contrast, poorly controlled T1D in association with characteristic diabetic complications, such as neuropathy or renal glomerulopathy, resulted in consistent reduction of androgen blood levels (Baccetti et al., 2002; Maric et al., 2010) . Unfortunately, most studies did not take into account the modern medical care of T1D patients, such as novel glucose measuring technologies, self-managed glucose control or flexible concepts of insulin therapy.
Taken together, clinical studies revealed a lack of solid consensus and even some contradictions concerning the effect of T1D and the hyperglycemic state on male fertility. This is caused by a variability of factors, such as the duration of exposure to glucose dysregulation, the age of the individuals, the techniques used to determine semen quality and testicular morphology, dietary habits, lifestyle factors and many others. In addition, the molecular mechanisms by which hyperglycemia may alter testicular functioning are not easy to unveil in humans, partly owing to ethical concerns against testis biopsy. Therefore, the vast majority of the clinical studies lack a molecular approach to investigating the effects of hyperglycemia, glucose transport and metabolism in sperm and testicular cells and, thus, those mechanisms remain largely unknown. Therefore, the use of animal models has been crucial to provide a more detailed molecular insight on the effects of hyperglycemia on the male reproductive system and fertility.
Animal studies
The first studies using diabetic rat models reported a decrease in male fertility after mating with wild-type females (Frenkel et al., 1978) . These studies also revealed that male diabetic rodents have diminished body and reproductive organ weight, lower testicular and epididymal sperm content, and lower sperm motility (Hassan et al., 1993; Soudamani et al., 2005; Scarano et al., 2006) . Moreover, the BB Wistar rats, a model that spontaneously develops T1D and thus a good model to study the effects of hyperglycemia through time, showed severe gonadal dysfunction and compromised male fertility (Murray et al., 1981 (Murray et al., , 1983 with histological studies revealing a reduction in the size of the tubules and an increased epididymal lumen (Soudamani et al., 2005) as hallmarks for hyperglycemia-induced reproductive dysfunction. Sperm changes, particularly decreased concentration and motility, were also described in Goto-Kakizaki (GK) diabetic rats (Amaral et al., 2006) . Rats with diabetes induced using the toxin Streptozocin (STZ) presented altered sex behavior, decreased gonadal weight, decreased sperm quantity and sperm motility (Hassan et al., 1993) , also highlighting that diabetic individuals present several problems in epididymal function (Soudamani et al., 2005) . In fact, it was shown that DM causes a regression of the epididymis, decreasing the absolute weight of caput, corpus and caudal regions, accompanied by a reduction in tubular diameter and a lumen devoid of spermatozoa (Soudamani et al., 2005) . Still, STZ-induced hyperglycemic rats sustain overall a fertilizing ability in spite of pathologies of a variable number of sperm parameters (Scarano et al., 2006) . Moreover, tight glycemic control was able to restore sperm counts and motility in the STZ-induced diabetic model (Seethalakshmi et al., 1987) , as well as the morphology of the epididymis (Soudamani et al., 2005) . Although the molecular mechanisms involved were not investigated, these studies illustrate that hyperglycemia, or poor glycemic control, are (at least in part) responsible for the deleterious effects of DM in male reproductive health. Indeed, uncontrolled glycemia was shown to be a major contributor to testicular dysfunction in diabetic male rats (Cameron et al., 1990) . Hyperglycemic rats were also reported to have altered steroidogenesis (Kim and Moley, 2008) , exhibiting a decrease in serum testosterone levels and negative outcomes after mating (Tsounapi et al., 2017a) . Reduction of testosterone was associated with an enhancement of testicular glycogen synthesis, suggesting that hyperglycemia induces a metabolic and hormonal reprogramming in the testis, partly through decreased enzyme activity of phosphofructokinase 1 and lactate dehydrogenase (Rato et al., 2015a) . DM is reported to increase cellular glucose uptake and to reduce the production of lactate by testicular cells, while also increasing the levels of cholesterol, nonesterified fatty acids, triglycerides and phospholipids in rat testicular tissues (Sharaf et al., 1978) . The biochemical responses of Sertoli and peritubular cells exposed to diabetic glucose levels showed that their metabolic machinery was indeed modulated by glucose (Hutson, 1984) . In addition, hyperglycemia also induces severe alterations in lipid metabolism, particularly the hydrolysis of triglycerides, fatty acyl esters of cholesterol, and steroid hormones, and studies have proved that a normal lipid metabolism is essential for normal spermatogenesis (Chung et al., 2001) . High-energy diets inducing mild hyperglycemia were reported to compromise male fertility (reviewed in (Rato et al., 2014a) ). It was recently shown that mild hyperglycemia in prediabetic rats results in increased abnormal sperm morphology (Rato et al., 2013) .
The oxidative balance of the male reproductive tract has also been studied and it was shown that hyperglycemia induces oxidative stress (OS) and initiates apoptosis, among other deleterious effects (Amaral et al., 2008) . Indeed, it is known that hyperglycemia induces cellular OS due to excessive reactive oxygen species (ROS) production and decreased antioxidant defences (Tabak et al., 2011) . The production of ROS has severe deleterious effects on sperm quality and function (for review see (Aitken et al., 2016) ). In addition, high levels of ROS are detrimental to fertility potential in natural and assisted conception (Agarwal et al., 2003) . Hyperglycemia-induced superoxide overproduction inhibits, among others, glyceraldehyde-3-phosphate dehydrogenase, PKC and aldose reductase in endothelial cells (Nishikawa et al., 2000) , which results in lower antioxidant defences, overproduction of ROS and mitochondrial dysfunction. Mitochondrial biogenesis is also sensitive to ROS production (Yu et al., 2006) and hyperglycemia inhibits the testicular antioxidant capacity in mitochondria (Palmeira et al., 2001) . Mild hyperglycemia decreases mitochondrial DNA content, testicular mitochondrial complex III and adenylate energy charge, which were reported to be followed by a repression of respiratory capacity and increased OS (Rato et al., 2014b) . This effect was suggested to be modulated by peroxisome proliferator-activated receptor γ coactivator 1 α and Sirtuin 3 (Rato et al., 2014b) , which may be essential to control the hyperglycemia-mediated effects on testis.
In STZ-induced hyperglycemic rats, an upregulation of the proapoptotic factors Bax, Bad and c-Jun N-terminal kinases was also reported, which was correlated with an increase in germ cell death (Koh, 2007a (Koh, , 2007b . OS markers were also increased in the epididymis of prediabetic rats, illustrating that sperm are exposed to ROS during storage, even in mild hyperglycemic conditions (Dias et al., 2016) . In addition, sperm cells are highly susceptible to ROS since their cell membranes are rich in polyunsaturated fatty acids (Aitken et al., 2012) and apoptosis is known to be mediated by OS and thus exerts an effect in sperm (Grunewald et al., 2008; Aitken and Koppers, 2011) . Indeed, hyperglycemia-mediated ROS are suggested to be a main mechanism by which DM affects male reproductive health (Roessner et al., 2012) and high levels of ROS were detected in the ejaculates of diabetic men (Roessner et al., 2012) . STZ-induced hyperglycemia promotes impaired sperm parameters, with an increase of total oxidant levels accompanied by a decrease in antioxidant levels (Kilarkaje et al., 2014) , illustrating that oxidative unbalance is a key hallmark for hyperglycemia in testis. This is supported by multiple studies showing that intervention using antioxidative agents was able to rescue hyperglycemia-induced oxidative damage in the male reproductive tract (Khaneshi et al., 2013; Sebai et al., 2015; Tsounapi et al., 2017a,b; Shi et al., 2017; Yigitturk et al., 2017) . Summarized findings from these investigations are presented in Table III, while  Table IV provides an overview on the observed reproductive dysfunction and postulated mechanisms.
Glucose receptor expression
Even though sodium dependent and facilitative glucose transporters are the main transport mechanisms for glucose to pass into the intracellular space, surprisingly little research has been done on the regulation of these transporters in the context of hyperglycemia-induced male infertility. Kim and Moley (2008) have described the presence of Scl2a8, the gene encoding Glut8, in the intra-cellular compartment within the testis, as well as in the midpiece, principal piece, and the acrosomal region of sperm of diabetic mice, with testicular expression being reduced compared to wild-type controls. This goes Continued along with a significant reduction in Scl2a8 mRNA. In contrast, a change of Glut8 due to hyperglycemia was not confirmed in rat testis (Gomez et al., 2009) . Further, Slc2a9, the gene encoding Glut9, was not present within the testis, while it was localized in the midpiece and acrosomal region of sperm, with a significant reduction in type 1 diabetic mice (Kim and Moley, 2008) .
Activin signaling
Activins and the antagonistic inhibins are both members of the transforming-growth-factor β (TGF-β) superfamily and were first described based on their ability to regulate FSH synthesis and secretion by the anterior pituitary (Dias et al., 2009; Barakat et al., 2012) . Both are highly conserved across different species, and critical for germ and Sertoli cell development as well as for adult testis function.
Members of the TGF-β superfamily are known to signal through the formation of a multimeric receptor complex formed of two distinct receptor subunit classes (Barakat et al., 2012; Loveland and Hedger, 2015; Young et al., 2015) , further enabling the phosphorylation of downstream signaling molecules such as regulatory Smads (R-Smads) 2 and 3. Being phosphorylated, these Smads are able to bind to the common Smad4 in order to build a complex, which can translocate into the nucleus to affect gene transcription (Barakat et al., 2012; Loveland and Hedger, 2015; Young et al., 2015) . Both activins and inhibins have been well described for their role in the regulation of reproduction, and have also been shown to function in both a paracrine and autocrine manner in each organ of the hypothalamic-pituitary-testis axis. Activin is known to stimulate GnRH release from the hypothalamus and FSH release from the pituitary. It can further increase the number of GnRH receptors on the surface of gonadotrophes and augment the GnRH-mediated transcriptional activation of GnRH receptors in order to enhance the pituitary response to GnRH (Barakat et al., 2012) . In the testis itself, the local production of activin and the control of its signaling pathway are critical for germ and Sertoli cell development as well as for adult testis function (Barakat et al., 2012) . The role of the activins in reproductive biology has been extensively reviewed recently (Wijayarathna and de Kretser, 2016) .
Little is known of the actions of the activin family of proteins with regard to hyperglycemia. Several studies have proposed an important role for certain members of the TGF-β superfamily in the pathogenesis of diabetes by maintaining β-cell function under physiological conditions. Specifically, activins A and B, as well as their binding protein follistatin, have been shown to be involved in the regulation of glucose metabolism and inflammation (Szabat et al., 2010; Andersen et al., 2011; Hashimoto and Funaba, 2011; Chen et al., 2013; Ofstad et al., 2013; Wu et al., 2013) . Moreover, since gene expression of the activin βB subunit, as well as that of the canonical activin receptors ALK4, ActRIIA and ActRIIB, has been demonstrated in the pancreatic bud in mice (Dichmann et al., 2003) , and the activin βA subunit was localized in α, β and δ cells of the pancreatic islet (Ogawa et al., 1993; Yasuda et al., 1993) , the involvement of activins in the development and onset of diabetes seems likely. Hashimoto and Funaba reported that activins A and B are regulators of the differentiation and activation of pancreatic β-cells and that they are, moreover, involved in controlling the response of insulin target cells (Hashimoto and Funaba, 2011) . Additionally, they have been proposed to modulate events involved in insulin sensitivity in a tissue-dependent manner and, therefore, regulate whole-body insulin responsiveness (Hashimoto and Funaba, 2011) . Hence, activin A is capable of reducing target tissue sensitivity to insulin, while activin B was shown to enhance insulin gene transcription (Hashimoto and Funaba, 2011; Wu et al., 2012) . This is further supported by the finding that activin enhances glucose stimulated insulin secretion, and augments the expression of genes characteristic of mature β-cells, such as insulin, solute carrier family 2 (Scl2a2 or Glut2) and Pc2, which suggests that activin is actively involved in β-cell differentiation.
In this context, recent work from our group (Maresch et al., 2017) suggests that hyperglycemia leads to testicular disruption accompanied by an upregulation of testicular activin A levels and, in turn, to a dysregulation of the downstream signaling. We have found that under severe hyperglycemic conditions, the activin type II receptors are significantly downregulated followed by a specific upregulation of pSmad3 and Smad4. These findings further support a significant role for the activins in hyperglycemia-induced changes in male reproductive biology.
Hyperglycemia and epididymal function
While the testis is regarded as an immune privileged organ owing to the presence of the BTB, cells within the epididymis are more susceptible to metabolic induced damage. The epididymis is composed of the caput, mid-piece and cauda and is important for the maturation and motility of spermatozoa, the latter increasing during epididymal transit. As an androgen-dependent organ, it is influenced by testicular testosterone secretion and obviously is dependent on the testis for the production of sperm and thus remains under the direct and indirect influence of testicular pathologies. To date, only a few studies have investigated epididymal pathologies in the context of hyperglycemia-induced changes, showing that high levels of circulating blood glucose affect the histologic architecture of the epididymal duct, specifically resulting in a reduced germ cell population, loss of stereocilia, clumping of epithelial cells and lipid vacuolization along with inflammatory infiltrations, exfoliated cells and round spermatids with cribriform changes (La Vignera et al., 2015; Korejo et al., 2016) . These changes may, in part, be related to OS (Mallidis et al., 2007a; Maremanda et al., 2016) and subsequent hypozincemia (Maremanda et al., 2016) . Hypozincemia is a common comorbidity in diabetic patients and was recently investigated in the context of diabetes-induced male reproductive dysfunction. Results from this study show that diabetic rats had reduced zinc contents in serum, testis, and sperm with a subsequent increase in OS. Oral zinc supplementation was able to attenuate these changes (Maremanda et al., 2016) .
Hyperglycemia in further parts of the reproductive tract
In the context of male reproductive dysfunction, the majority of studies have investigated changes in testicular morphology and spermatogenesis. Studies investigating hyperglycemic changes in the distal parts of the reproductive tract, such as the efferent ducts, seminal vesicles or the prostate are rare. Hyperglycemic changes within the prostate were previously related to changes in metabolic status in the onset of benign prostatic hyperplasia, possibly leading to subsequent sperm abnormalities (Vignozzi et al., 2014) . Studies examining hyperglycemiainduced prostatic changes have shown that this condition interferes with prostate growth and leads to atrophic changes in the prostate gland (Ribeiro et al., 2008; Favaro et al., 2009; Porto et al., 2011) . These effects were suggested to be zone dependent because of differences in lobe response in diabetic rodents (Favaro et al., 2009; Porto et al., 2011) . Histological examination revealed that hyperglycemia was related to atrophy in prostatic secretory epithelial cells, stromal hypertrophy, an increase in inflammatory cells, and prostatic intraepithelial neoplasia, as well as dilated organelles in the secretory process (Cagnon et al., 2000; Carvalho et al., 2003; Ribeiro et al., 2008) . Recent studies showed further that hyperglycemia in diabetic men was inversely related to serum levels of prostate-specific antigen (PSA). This was found to be independent of age, BMI, androgen levels, and medication use as well as the level of hyperglycemia, suggesting a direct effect of hyperglycemia on PSA levels (Ozbek et al., 2014; Sarma et al., 2015) .
Besides effects on the prostate, hyperglycemia resulted in a reduction in seminal vesicle weight in diabetic rodents (Hutson et al., 1983; Schoeller et al., 2012) and a higher fundus-to-body antero-posterior diameter ratio with a lower pre-and post-ejaculatory difference in diabetic men (La Vignera et al., 2013) . This might be related to changes in the sympathetic innervation of the seminal vesicle (Morrison et al., 2006) or an increase in OS (Tsounapi et al., 2017a) .
It has been known since 1963 that RE occured commonly in men with diabetes, probably contributing to infertility (Greene et al., 1963; Bourne et al., 1971; Fedder et al., 2013; Kam et al., 2017) . Thus, diabetics were found to present more frequently with RE compared to their age-matched controls. While this observation could not be associated with BMI, waist circumference, blood pressure, HbA1c, high-density lipoprotein cholesterol, triglycerides, fasting glucose or s-testosterone, it seemed to progress with the duration of the disease (Fedder et al., 2013) . Changes in the sympathetic innervation of the seminal vesicle, possibly in the context of diabetic autonomic neuropathy, are thought to be causative for this pathology (Morrison et al., 2006; Fedder et al., 2013) .
Discussion
T1D, associated with hyperglycemia, is one of the most prominent public health threats in modern societies with a rapidly rising prevalence. This is accompanied by a rise in the number of childhood and adolescent males with T1D, affecting an increasing number of men of reproductive age (Guariguata et al., 2014) .
Up to the present time, a large number of studies have described a negative impact of DM on male reproductive function leading to degenerative changes within the testis and epididymis, erectile and ejaculatory dysfunction, as well as a reduction in semen volume, sperm counts, sperm motility and altered sperm morphology. However, these data have not discriminated the influence of hyperglycemia itself from other metabolic traits such as obesity or insulin resistance. Hence, the impact of metabolic changes on male reproductive health are often associated with dyslipidemia and inflammation, conditions that are not always related to hyperglycemia per se (Kasturi et al., 2008) .
Therefore, the present review of clinical and animal studies provides the most comprehensive analysis to date of the associations between hyperglycemia and male factor infertility.
A systematic search yielded a series of case-control studies suggesting that uncomplicated T1D was not associated with the hallmarks of male infertility or hypogonadism. However, poorly controlled blood glucose in conjunction with late stage diabetic complications reduced both sperm counts and testosterone blood levels. Intervention studies with T1D patients, informing on testicular mechanisms and applicable for healthcare practice guidelines, were hardly identified.
Observed changes in animal models included testicular disruption, spermatogenic dysfunction, increased germ-cell apoptosis, hormonal dysregulation and altered sperm parameters, as well as a dysfunction in distal reproductive organs. While the analyzed clinical studies rarely investigated the underlying mechanisms of the observed pathologies, data from animal studies suggested that impaired function of the HPG-axis, increased DNA damage, perturbations in the AGE/RAGE system, OS, increased ERstress, modulation of cellular pathways, impaired mitochondrial function and disrupted sympathetic innervation were reported causes.
Future treatment aspects in the protection from diabetes-induced sperm failure Perrard-Sapori et al., 1987; Griffeth et al., 2014) , with a recent study suggesting that the insulin might also be released into the blood stream under the regulation of the HPG-axis (Schoeller et al., 2012) . Moreover, there is evidence that insulin can regulate human sperm fertilization capacity through regulation of glucose metabolic pathways during sperm acrosome formation and capacitation (Aquila et al., 2005) .
The regulation of insulin levels directly impacts on the expression of INSR, as well as IGF1R, leading to the activation of downstream signaling pathways involved in proliferation, differentiation, metabolism and cell survival (Avruch, 1998; Taniguchi et al., 2006) . Thus, upregulation of insulin results in the downregulation of Insr and Igf1r, and vice versa (Friedman et al., 1997; Franko et al., 2012; Vigneri et al., 2016) . A recent report suggests that the lack of Insr and Igr1r in Sertoli cells results in a 75% reduction in testis size and daily sperm production (Pitetti et al., 2013) . However, there is no clear evidence if blood insulin levels, either high or low, will affect fertility in the same way as testicular insulin synthesized by Sertoli cells.
Treatment for hyperglycemia. A progression of diabetic vascular complications despite reversal of hyperglycemia was observed in the EDIC (Epidemiology of Diabetes and Complications) study (Diabetes et al., 2015) . This durable effect of prior hyperglycemia on the progression of body-wide vasculopathy was defined as metabolic memory. Enhanced glycation reactions, OS, and induction of the innate immune system were shown to facilitate the phenomenon. On the other hand, metabolic memory is also operative in persistent salutary effects of a period of intensive insulin therapy after differences in glycemia between the original intensive and conventional treatment cohorts have disappeared (Writing Team for the Diabetes, Complications Trial/ Epidemiology of Diabetes, and Complications Research, 2002) . In a series of identically designed large controlled trials, intensive insulin treatment aimed at near-normal blood glucose levels, while conventional treatment was performed to deflect severe metabolic disturbances, such as ketoacidosis and weight loss. Apart from empowering the diabetic patient to organize treatment, another essential precondition of an intensive insulin regimen is its implementation early in the course of diabetes. If such intervention is delayed or near-normal glycemia is not attained, the momentum of complications is harder to slow down. Metabolic memory is now accepted as part of the pathogenesis of retinopathy and other micro-and macrovascular complications of diabetes. However, until now its role in testicular pathogenesis has been poorly investigated, with studies in ruminants suggesting that, depending on its availability, glucose impacts on the reproductive axis via insulin and leptin secretion, which in turn regulate GnRH output (Blache et al., 2006) .
As there are no established guidelines of medical care in diabetesinduced infertility, other hormonal approaches with GH and hCG were used in medical practice (Moss et al., 2013) . GH was shown to stimulate IGF1 formation, improving sperm maturation in a paracrineautocrine manner, while hCG triggers Leydig cell production of testosterone. Clomiphene and aromatase inhibitors appeared not to negatively impact sperm and were even shown to be beneficial in the treatment of male infertility, but were not tested for the treatment of hyperglycemia (Chua et al., 2013) . Further, exogenous testosterone and anabolic steroids obviously had detrimental effects as they suppressed the HPG-axis. Hence, none of these options can be recommended in conditions of hyperglycemia at present owing to the lack of quality research data. By contrast, insulin efficacy in handling hyperglycemia is profoundly supported by human studies and safe in routine clinical use. As such, a well-conducted trial of up-to-date insulin treatment, taking metabolic memory effects into account and examining male fertility as primary objective, will be most warranted.
Oral hypoglycemic agents
Besides insulin as the major glucose regulatory agent, oral hypoglycemic agents have been discussed in the control of hyperglycemia and subsequent male reproductive dysfunction. As such, metformin, known for its ability to suppress gluconeogenesis in the liver, was previously shown to improve semen characteristic in patients with metabolic syndrome owing to a reduction in insulin resistance, sex hormone-binding globulin levels, as well as an increase in serum androgen levels (Morgante et al., 2011) . This is further supported by evidence from an animal study in rats showing that metformin is able to abrogate not only the decrease in testis weight, but also the decrease in number of spermatogonia, Sertoli cells and Leydig cells . In vitro experiments from our group on metformintreated Sertoli cells further supported the benificial effects of metformin as it provides nutritional support by increasing lactate production and has an anti-apoptotic effect on developing germ cells (Alves et al., 2014) .
Research on further oral hypoglycemic agents, such as glitazones, alpha-glucosidase or SGLT2 inhibitors, GLP-1 analogs, or sulphonylureas, in the context of male reproductive health remains scarce. Pioglitazone was shown to improve erectile function in rats, however, to the best of our knowledge there are no studies on diabetic animals or patients to date (Aliperti et al., 2014) . Moreover, as seminal alphaglucosidase has been used as a clinical marker of epididymal function (Cooper et al., 1990) , the use of alpha-glucosidase inhibitors in the treatment of diabetes-induced reproductive dysfunction is indicated, but has not been adapted in controlled studies so far.
Even though some oral hypoglycemic agents were shown to improve male reproductive potential, results have to be taken with caution in terms of hyperglycemia-induced male reproductive dysfunction as these drugs were approved as anti-diabetic agents in the treatment of T2D, which often occurs in the context of the metabolic syndrome and, thus, other comorbidities. Therefore, these drugs would need a thorough re-examination in the context of male reproductive dysfunction.
Follistatin
Recent evidence on the underlying mechanisms of hyperglycemiainduced male reproductive dysfunction identified a dysregulation within the activin family of proteins as possible target for future treatments (Maresch et al., 2017) . In light of this finding, follistatin, a key regulator of the biological actions of the activins, should be evaluated as a therapeutic agent. Originally described as FSH suppressing Protein (Robertson et al., 1987; Ueno et al., 1987) , follistatin has the capacity to bind to activins A and B with high affinity, negatively regulating their bioactivity (Nakamura et al., 1991) . This ability of follistatin was previously used to counteract the actions of the activins in the treatment of diseases and pathologies that are associated with activin upregulation. Hence, subcutaneous follistatin treatment attenuated the radiation-induced fibrotic response in irradiated mice (Forrester et al., 2017) , while follistatin gene therapy proved to be useful in the treatment of inclusion body myositis in men (Mendell et al., 2017) . In mouse models of cancer cachexia, overexpression of follistatin via subcutaneous vector injection ameliorated the cachectic effects of activin A .
To date, there are no therapeutic attempts to target the regulation of activin A in reproductive disorders. Therefore, advancements in this area would definitely be beneficial to the field of reproductive pathology. In this respect, the finding that testicular activin A signaling is disrupted in type 1 diabetic males makes follistatin an interesting target for the investigation within therapeutic purposes.
Poly-ADP-ribose-polymerase inhibitors
While erectile dysfunction is an example of a common disorder clearly linked to macrovascular pathology, impairment of spermatogenesis may be extrapolated from direct biochemical consequences of excessive glucose, as delineated before.
The process of spermatogenesis is characterized by the transient occurrence of physiological DNA strand breaks caused by the transition from histone-to protamine-based chromatin. Notably, these processes involve the formation of poly(ADP-ribose) (PAR) and thereby induce DNA damage signaling (Meyer-Ficca et al., 2011) . Generated through the binding of PAR polymerases 1 and 2 (PARP1 and PARP2, respectively) to single strand DNA breaks, poly(ADPribosyl)ation is known to be involved in multiple cellular processes including DNA repair, genomic stability, and programmed cell death under physiological conditions (Kiss and Szabo, 2005) . Under pathophysiological conditions, however, activation of PARP leads to cellular dysfunction and necrotic cell death, due to a reduction in the rate of glycolysis and mitochondrial respiration (Kiss and Szabo, 2005) . In this context, several studies in diabetic subjects have identified an increase in PARP related to oxidative and nitrosative stress, as well as genomic instability (Kiss and Szabo, 2005; Horvath et al., 2009) . Investigations in the male reproductive tract further show an upregulation of PARP within the testis of diabetic rats (Abdelali et al., 2016) . This occurs in parallel with an increase in diabetes-induced DNA damage in the reproductive tract, as described previously.
Inhibition of PARP was used in numerous studies and effectively ameliorated muscular activity in ischemia reperfusion in diabetic rats (Long et al., 2013) , and PARP activity in the blood of T2D patients (Shrikhande et al., 2006) . However, to date there is only one study that investigated the effects of PARP inhibitors on the testis, showing no effects in T1D rats (Abdelali et al., 2016) . Still, searching for nonglucose lowering agents will be desirable as there will be treatments needed in case of delayed or failing implementation of insulin treatment.
Limitations and strengths
Some limitations of our study should be acknowledged. Although broad search terms were used, and reference lists were hand searched, possibly not all publications have been identified. In addition, our search strategy was limited to Pubmed and Cochrane databases, and not EMBASE or other databases. However, the main scientific journals are indexed in Pubmed database. Higher evidence levels were scarce in clinical trials even following assessment of bias sources and quality scores by two authors independently. The review of basic research studies showed that they opened new pathways of research on mechanisms involved in the effects of hyperglycemia, but altogether were far from conclusive and left many issues in humans unanswered.
Notwithstanding these limitations, this review is the most up to date and exhaustive review of studies on the impact of hyperglycemia on male reproductive function carried out in accordance with the PRISMA guidelines and a quality-validated, registered protocol. Future studies along the indicated lines are needed to confirm our conclusions.
Conclusions
Hyperglycemia is a major health concern with a growing incidence, affecting an increasing number of men in their reproductive years. While clinical outcomes of hyperglycemia-induced male reproductive dysfunction were covered in studies on T1D, the designs were variable and important patient information was not available. Moreover, only a few studies addressed the underlying mechanisms in the context of hyperglycemia and disrupted fertility, suggesting impaired function of the HPG-axis, increased DNA damage, perturbations in the AGE/RAGE system, OS, increased ER-Stress, modulation of cellular pathways, impaired mitochondrial function and disrupted sympathetic innervation as possible causes (Fig. 4) . However, mechanistic studies identifying the pathological details in a conclusive way, were missing and would be essential for the understanding of these interactions.
Given that the fact that insulin is the significant factor in terms of glucose regulation, interventions using insulin to regain normoglycemia should be adapted to prove the suggested underlying mechanisms. Furthermore, new treatment options, such as follistatin or poly-ADP-polymerase inhibition, should be investigated when activin dysregulation or DNA damage were identified as playing a role.
In the future, hyperglycemia should be investigated in more detail on a molecular basis in order to fully understand the impact on male reproductive health.
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Supplementary data are available at Human Reproduction Update online. Figure 4 Effects of hyperglycemia on male reproductive tract and reproductive health. The increased glycemia levels impair testicular function by disrupting both steroidogenesis and spermatogenesis. Furthermore, hyperglycemia also impairs male reproductive function, lowering sperm reproductive parameters owing to increased OS. FFA, free fatty acids; PLP, phospholipids; TG, triglycerides; Blue box -clinical studies; Yellow box -animal studies; Green box -intersectional studies; Bidirectional arrows, alteration; Down arrows, decrease; Up arrows, increase;?, non-consensual alteration.
